Research analysts at StockNews.com began coverage on shares of Revance Therapeutics (NASDAQ:RVNC – Get Free Report) in a report released on Tuesday. The brokerage set a “hold” rating on the biopharmaceutical company’s stock.
Several other brokerages also recently weighed in on RVNC. Needham & Company LLC reiterated a “hold” rating on shares of Revance Therapeutics in a report on Friday, January 17th. Barclays cut their price objective on shares of Revance Therapeutics from $7.00 to $3.00 and set an “equal weight” rating on the stock in a research note on Monday, December 23rd. Finally, Mizuho reduced their target price on shares of Revance Therapeutics from $6.66 to $3.10 and set a “neutral” rating for the company in a report on Tuesday, December 10th. Nine research analysts have rated the stock with a hold rating and one has assigned a buy rating to the company’s stock. According to MarketBeat, Revance Therapeutics presently has a consensus rating of “Hold” and a consensus price target of $8.39.
View Our Latest Research Report on RVNC
Revance Therapeutics Stock Performance
Hedge Funds Weigh In On Revance Therapeutics
Several institutional investors have recently made changes to their positions in the company. Natixis acquired a new stake in Revance Therapeutics during the fourth quarter valued at $31,000. Two Sigma Securities LLC purchased a new stake in shares of Revance Therapeutics during the 4th quarter worth about $35,000. Alpine Global Management LLC acquired a new stake in shares of Revance Therapeutics during the 4th quarter valued at about $37,000. FORA Capital LLC acquired a new stake in shares of Revance Therapeutics during the 3rd quarter valued at about $54,000. Finally, RPO LLC purchased a new position in shares of Revance Therapeutics in the 4th quarter valued at about $55,000. 97.70% of the stock is owned by hedge funds and other institutional investors.
About Revance Therapeutics
Revance Therapeutics, Inc, a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company’s lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis.
Recommended Stories
- Five stocks we like better than Revance Therapeutics
- How to Profit From Value Investing
- Can TikTok Stock Picks Really Make You Rich?
- About the Markup Calculator
- The “Quality” Rotation: Back to Basics Investing
- There Are Different Types of Stock To Invest In
- Occidental Petroleum: 4 Reasons to Love These Prices
Receive News & Ratings for Revance Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revance Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.